ERBB2 and adenocarcinoma: Studies demonstrated weakly inhibiting EGFR tumor suppression activity in SK-OV-3 cell lines when HER2 knockdown occurred in vivo, and potent tumor suppression was exhibited in HER2-overexpressing adenocarcinoma xenograft and FVB-2/N(neu) transgenic breast cancer mouse models [54].